We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Certain Blood Types Could Be Associated with Greater Risk of Contracting COVID-19, Confirms New Study

By HospiMedica International staff writers
Posted on 04 Mar 2021
Illustration
Illustration
As researchers around the world work to identify and address risk factors for severe COVID-19, there is additional evidence that certain blood types could be associated with greater risk of contracting the disease.

The findings of one of the first laboratory studies conducted by researchers at Brigham and Women’s Hospital (Boston, MA, USA) suggest that SARS-CoV-2, the virus that causes COVID-19, is particularly attracted to the blood group A antigen found on respiratory cells. In the study, researchers assessed a protein on the surface of the SARS-CoV-2 virus called the receptor binding domain, or RBD. The RBD is the part of the virus that attaches to the host cells, so it is an important research target for understanding how infection occurs. The team assessed synthetic blood group antigens on respiratory and red blood cells found in blood group A, B, and O individuals, and analyzed how the SARS-CoV-2 RBD interacted with each unique blood type. They discovered that the RBD had a strong preference for binding to blood group A found on respiratory cells. It did not display a preference for blood group A red blood cells, or other blood groups found on respiratory or red cells. The capacity of the RBD to preferentially recognize and attach to the blood type A antigen found in the lungs of blood type A individuals may provide insight into the potential link between blood group A and COVID-19 infection.

Based on their observations, the team sought to determine whether a similar binding preference existed for the RBD of SARS-CoV, the virus that causes severe acute respiratory syndrome (SARS). Although the makeup of the virus differs, the SARS-CoV RBD exhibited the same preference to bind to the group A antigens on respiratory cells. The team has emphasized that their findings alone could not fully describe or predict how coronaviruses like SARS-CoV-2 and SARS-CoV would affect patients of various blood types. While further research is needed to understand that influence, the research adds to findings from earlier studies suggesting a possible link between blood type and COVID-19 susceptibility and severity.

“It is interesting that the viral RBD only really prefers the type of blood group A antigens that are on respiratory cells, which are presumably how the virus is entering most patients and infecting them,” said study author Sean R. Stowell, MD, PhD, of Brigham and Women’s Hospital. “Blood type is a challenge because it is inherited and not something we can change. But if we can better understand how the virus interacts with blood groups in people, we may be able to find new medicines or methods of prevention.”

Related Links:
Brigham and Women’s Hospital

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Radial Artery Compression Device
TR Band
New
Instrument Cabinet
TRZY-068

Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more